Investigation of Serum Cardiotrophin-1 Concentrations in Pregnant Women with Gestational Diabetes Mellitus

Abstract

Objective We aimed to investigate cardiotrophin-1 (CT-1) concentrations in the serum of pregnant women with gestational diabetes mellitus (GDM).

Materials and methods This prospective non-interventional cohort study was conducted with 160 pregnant women who applied to the Umraniye Training and Research Hospital, Department of Obstetrics and Gynecology between October 2022 and May 2023. The GDM group was formed from 80 pregnant women who were diagnosed with GDM according to the 75-g OGTT. The control group consisted of 80 healthy pregnant women who were matched with the GDM group in terms of age and body mass index and had a normal 75-g OGTT result. Two groups were compared in terms of maternal serum CT-1 concentrations.

Results Both groups were similar in terms of demographic features and the gestational week at blood sampling for CT-1 (p>0.05 for each). The mean maternal serum CT-1 concentration was found to be 1420.9 pg/ml in the GDM group, while it was determined as 1455 pg/ml in the control group (p=0.738). When the GDM and control groups were divided into two subgroups, normal weight and overweight according to the participants’ BMI, serum CT-1 concentrations were found to be similar in these four groups (p=0.084). When the GDM group was divided into two groups of diet-only and the insulin-using group for blood glucose regulation and compared with the control group, the three groups were also similar in terms of serum CT-1 concentrations (p=0.189).

Conclusion CT-1 is an adipokine involved in the regulation of glucose metabolism and has been suggested to be associated with the pathophysiology of diabetes mellitus. In this study, serum CT-1 concentrations were found to be similar in the group with GDM and the group with normal glucose tolerance. Whether CT-1 contributes to the development of GDM is currently unclear and requires further investigation.

Key words

Cardiotrophin-1 - diabetes mellitus - gestational diabetes mellitus - oral glucose tolerance test

Publication History

Received: 26 July 2023

Accepted after revision: 03 November 2023

Article published online:
20 December 2023

• References

• 1 ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol 2018; 131: e49-e64 DOI: 10.1097/AOG.0000000000002501.
• 2 Alexopoulos A-S, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: A review. JAMA 2019; 321: 1811 DOI: 10.1001/jama.2019.4981.
• 3 Sun H, Saeedi P, Karuranga S. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119 DOI: 10.1016/j.diabres.2021.109119.
• 4 Wang H, Li N, Chivese T. et al. IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s Criteria. Diabetes Res Clin Pract 2022; 183: 109050 DOI: 10.1016/j.diabres.2021.109050.
• 5 O’sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964; 13: 278-285
• 6 Lende M, Rijhsinghani A. Gestational diabetes: overview with emphasis on medical management. Int J Environ Res Public Health 2020; 17: 9573 DOI: 10.3390/ijerph17249573.
• 7 International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676-682 DOI: 10.2337/dc09-1848.
• 8 Pennica D, King KL, Shaw KJ. et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci 1995; 92: 1142-1146 DOI: 10.1073/pnas.92.4.1142.
• 9 Pennica D, Swanson TA, Shaw KJ. et al. Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine 1996; 8: 183-189 DOI: 10.1006/cyto.1996.0026.
• 10 López-Yoldi M, Moreno-Aliaga MJ, Bustos M. Cardiotrophin-1: A multifaceted cytokine. Cytokine Growth Factor Rev 2015; 26: 523-532 DOI: 10.1016/j.cytogfr.2015.07.009.
• 11 Latchman DS. Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent: Cardiotrophin-1. Int J Exp Pathol 2001; 80: 189-196 DOI: 10.1046/j.1365-2613.1999.00114.x.
• 12 Moreno-Aliaga MJ, Pérez-Echarri N, Marcos-Gómez B. et al. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab 2011; 14: 242-253 DOI: 10.1016/j.cmet.2011.05.013.
• 13 Hung H-C, Lu F-H, Ou H-Y. et al. Increased cardiotrophin-1 in subjects with impaired glucose tolerance and newly diagnosed diabetes. Int J Cardiol 2013; 169: e33-e34 DOI: 10.1016/j.ijcard.2013.08.112.
• 14 Natal C, Fortuño MA, Restituto P. et al. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol-Endocrinol Metab 2008; 294: E52-E60 DOI: 10.1152/ajpendo.00506.2007.
• 15 Stephens J, Ravussin E, White U. The expression of adipose tissue-derived cardiotrophin-1 in humans with obesity. Biology 2019; 8: 24 DOI: 10.3390/biology8020024.
• 16 Liu J, Liu Z, Huang F. et al. Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes. Pharm 2007; 62: 925-929
• 17 Zvonic S, Hogan JC, Arbour-Reily P. et al. Effects of cardiotrophin on adipocytes. J Biol Chem 2004; 279: 47572-47579 DOI: 10.1074/jbc.M403998200.
• 18 Gamella-Pozuelo L, Fuentes-Calvo I, Gómez-Marcos MA. et al. Plasma cardiotrophin-1 as a marker of hypertension and diabetes-induced target organ damage and cardiovascular risk. Medicine (Baltimore) 2015; 94: e1218 DOI: 10.1097/MD.0000000000001218.
• 19 Hung H-C, Lu F-H, Wu H-T. et al. Cardiotrophin-1 is inversely associated with obesity in non-diabetic individuals. Sci Rep 2015; 5: 17438 DOI: 10.1038/srep17438.
• 20 López-Yoldi M, Stanhope KL, Garaulet M. et al. Role of cardiotrophin-1 in the regulation of metabolic circadian rhythms and adipose core clock genes in mice and characterization of 24–h circulating CT-1 profiles in normal-weight and overweight/obese subjects. FASEB J 2017; 31: 1639-1649 DOI: 10.1096/fj.201600396RR.